Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Speeding up for lympho-myeloid differentiation.

Blood·2025
Same author

Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome.

PLoS computational biology·2025
Same author

Math models expose myeloid bias mechanisms in hematopoiesis.

Blood·2025
Same author

Dynamics and bifurcations in a model of chronic myeloid leukemia with optimal immune response windows.

Journal of mathematical biology·2024
Same author

Protocol for the establishment of a serine integrase-based platform for functional validation of genetic switch controllers in eukaryotic cells.

PloS one·2024
Same author

Systematic Review of Available CAR-T Cell Trials around the World.

Cancers·2022
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Aug 20, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K

Modeling Patient-Specific CAR-T Cell Dynamics: Multiphasic Kinetics via Phenotypic Differentiation.

Emanuelle A Paixão1, Luciana R C Barros2, Artur C Fassoni3

  • 1Graduate Program, Laboratório Nacional de Computação Científica, Petrópolis 25651-075, Brazil.

Cancers
|November 26, 2022
PubMed
Summary
This summary is machine-generated.

Chimeric Antigen Receptor (CAR)-T cell therapy dynamics involve distinct phases influenced by patient and tumor factors. Assessing early CAR-T cell levels and non-exhausted cell fractions may predict treatment success.

Keywords:
CAR-T cell exhaustionantigen dependent CAR-T expansionfunctional CAR-T cellshematological malignanciesmemory pooltreatment outcomes

More Related Videos

Author Spotlight: Understanding Disease Mechanisms Through Real-Time Analysis of T-Cell Migration
06:42

Author Spotlight: Understanding Disease Mechanisms Through Real-Time Analysis of T-Cell Migration

Published on: May 24, 2024

1.6K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.5K

Related Experiment Videos

Last Updated: Aug 20, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K
Author Spotlight: Understanding Disease Mechanisms Through Real-Time Analysis of T-Cell Migration
06:42

Author Spotlight: Understanding Disease Mechanisms Through Real-Time Analysis of T-Cell Migration

Published on: May 24, 2024

1.6K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.5K

Area of Science:

  • Immunotherapy
  • Mathematical Biology
  • Oncology

Background:

  • Chimeric Antigen Receptor (CAR)-T cell immunotherapy enhances T cell cancer-fighting capabilities.
  • CAR-T cell responses exhibit complex multiphasic kinetics (distribution, expansion, contraction, persistence).
  • Response dynamics vary based on tumor type, CAR-T product, and patient characteristics.

Purpose of the Study:

  • To develop a mathematical model for multiphasic CAR-T cell dynamics.
  • To incorporate patient and product heterogeneities into CAR-T cell behavior analysis.
  • To identify potential biomarkers for predicting CAR-T cell therapy outcomes.

Main Methods:

  • Developed a mathematical model simulating CAR-T and tumor cell interactions.
  • Categorized CAR-T cells into functional, memory, and exhausted phenotypes.
  • Analyzed CAR-T cell dynamics across diverse hematological cancers and patient profiles.

Main Results:

  • The model accurately describes varied CAR-T cell dynamics in different patients and cancers.
  • Identified distinct CAR-T cell phenotypes influencing therapeutic outcomes.
  • Early CAR-T cell exposure (AUC) and non-exhausted cell fraction show potential as response markers.

Conclusions:

  • Mathematical modeling provides insights into CAR-T cell therapy complexities.
  • Understanding CAR-T cell phenotypes is crucial for optimizing immunotherapy.
  • Joint assessment of early exposure and cell phenotype may predict treatment efficacy.